Remdesivir Treatment Lacks the Effect on Mortality Reduction in Hospitalized Adult COVID-19 Patients Who Required High-Flow Supplemental Oxygen or Invasive …
C Huang, TL Lu, L Lin - Medicina, 2023 - mdpi.com
Background and Objectives: The therapeutic impact of remdesivir on hospitalized adult
COVID-19 patients is unknown. The purpose of this meta-analysis was to compare the …
COVID-19 patients is unknown. The purpose of this meta-analysis was to compare the …
Changes in Lymphocyte Subpopulations after Remdesivir Therapy for COVID-19: A Brief Report
R Cianci, MG Massaro, E De Santis, B Totti… - International Journal of …, 2023 - mdpi.com
Remdesivir (RDV) has demonstrated clinical benefit in hospitalized COronaVIrus Disease
(COVID)-19 patients. The objective of this brief report was to assess a possible correlation …
(COVID)-19 patients. The objective of this brief report was to assess a possible correlation …
Remdesivir Influence on SARS-CoV-2 RNA Viral Load Kinetics in Nasopharyngeal Swab Specimens of COVID-19 Hospitalized Patients: A Real-Life Experience
L Campogiani, M Iannetta, A Di Lorenzo, M Zordan… - Microorganisms, 2023 - mdpi.com
There are still conflicting data on the virological effects of the SARS-CoV-2 direct antivirals
used in clinical practice, in spite of the documented clinical efficacy. The aim of this …
used in clinical practice, in spite of the documented clinical efficacy. The aim of this …
Aged population and immunocompromised patients: impact on SARS-CoV-2 variants and treatment outcomes
Patients with an immunocompromised state are at risk of developing a long-term infection
from the coronavirus 2 that causes severe acute respiratory syndrome (SARS-CoV-2). It has …
from the coronavirus 2 that causes severe acute respiratory syndrome (SARS-CoV-2). It has …
[HTML][HTML] Perspective: repurposed drugs for COVID-19
K Na-Bangchang, S Porasuphatana… - Archives of Medical …, 2022 - ncbi.nlm.nih.gov
Methods Research articles and guidelines related to therapy of COVID-19 were searched
from the PubMed database. Results Only remdesivir and tocilizumab are medicines that …
from the PubMed database. Results Only remdesivir and tocilizumab are medicines that …
Substrate specificity and kinetics of RNA hydrolysis by SARS-CoV-2 NSP10/14 exonuclease
TL Dangerfield, KA Johnson - ACS Bio & Med Chem Au, 2022 - ACS Publications
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus that causes
COVID-19, continues to evolve resistance to vaccines and existing antiviral therapies at an …
COVID-19, continues to evolve resistance to vaccines and existing antiviral therapies at an …
[HTML][HTML] Effect of Paxlovid in COVID-19 treatment during the periods of SARS-CoV-2 Omicron BA. 5 and BN. 1 subvariant dominance in the Republic of Korea: a …
DH Kim, MG Yoo, NY Kim, SY Choi… - Osong Public Health …, 2024 - ncbi.nlm.nih.gov
Objectives This study was conducted to assess the efficacy of nirmatrelvir/ritonavir treatment
in patients with coronavirus disease 2019 (COVID-19), particularly those aged 60 years and …
in patients with coronavirus disease 2019 (COVID-19), particularly those aged 60 years and …
Retrospective analysis of the effectiveness of remdesivir in COVID-19 treatment during periods dominated by Delta and Omicron SARS-CoV-2 variants in clinical …
K Dobrowolska, D Zarębska-Michaluk… - Journal of Clinical …, 2023 - mdpi.com
Continuous evaluation of real-world treatment effectiveness of COVID-19 medicines is
required due to the ongoing evolution of SARS-CoV-2 and the possible emergence of …
required due to the ongoing evolution of SARS-CoV-2 and the possible emergence of …
Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the …
Background Comparative data on mortality in COVID-19 patients treated with molnupiravir
or with nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause …
or with nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause …
[PDF][PDF] Aged Population and Immunocompromised Patients: Impact on SARS-CoV-2 Variants and Treatment Outcomes. Biologics 2022, 2, 165–170
Patients with an immunocompromised state are at risk of developing a long-term infection
from the coronavirus 2 that causes severe acute respiratory syndrome (SARS-CoV-2). It has …
from the coronavirus 2 that causes severe acute respiratory syndrome (SARS-CoV-2). It has …